Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is recruited to the TNF receptor 1 to mediate proinflammatory signaling and to regulate TNF-induced cell death. RIPK1 deficiency results in postnatal lethality, but precisely why Ripk1 −/− mice die remains unclear. To identify the lineages and cell types that depend on RIPK1 for survival, we generated conditional Ripk1 mice. Tamoxifen administration to adult RosaCreER
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fl/fl mice results in lethality caused by cell death in the intestinal and hematopoietic lineages. Similarly, Ripk1 deletion in cells of the hematopoietic lineage stimulates proinflammatory cytokine and chemokine production and hematopoietic cell death, resulting in bone marrow failure. The cell death reflected cell-intrinsic survival roles for RIPK1 in hematopoietic stem and progenitor cells, because Vav-iCre Ripk1 fl/fl fetal liver cells failed to reconstitute hematopoiesis in lethally irradiated recipients. We demonstrate that RIPK3 deficiency partially rescues hematopoiesis in Vav-iCre Ripk1 
Ripk3
−/− progenitors remain TNF sensitive in vitro and fail to repopulate irradiated mice. These genetic studies reveal that hematopoietic RIPK1 deficiency triggers both apoptotic and necroptotic death that is partially prevented by RIPK3 deficiency. Therefore, RIPK1 regulates hematopoiesis and prevents inflammation by suppressing RIPK3 activation.
tumor necrosis factor | programmed necrosis | hematopoietic failure T he proinflammatory cytokine TNF stimulates receptorinteracting serine/threonine-protein kinase 1 (RIPK1) ubiquitination, NFκB and MAPK activation, and induction of apoptosis or necroptosis (1, 2) . TNF signaling via TNF receptor 1 (TNFR1) is highly regulated and results in the recruitment of several adapter proteins including TNFR1-associated death domain (TRADD) protein, the E3 ubiquitin ligases cellular inhibitor of apoptosis protein-1 and -2 (cIAP1/2), and TNFRassociated factor 2 (TRAF2) or 5, and the serine threonine death domain-containing kinase RIPK1 (complex I) (1) . We have demonstrated that the kinase activity of RIPK1 is not required for NFκB activation (3); rather, RIPK1 is modified by the addition of Lys63-linked and linear polyubiquitin chains (3) (4) (5) (6) . Polyubiquitinated RIPK1 then recruits NEMO/IκB kinase-γ (IKKγ) to mediate IKK activation and TAK1/TAB2/3 to mediate MAPK activation, resulting in antiapoptotic and proinflammatory gene expression (7, 8) . Deubiquitination of RIPK1 by cylindromatosis (CYLD) results in the formation of a cytosolic complex containing TRADD, Fas-associated death domain protein (FADD), caspase-8, and RIPK1 (complex IIa) (2) . Caspase-8 cleaves and inactivates RIPK1 and CYLD and stimulates apoptosis (9) (10) (11) . In the absence of caspase-8 or the presence of caspase inhibitors, TNF family members and potentially other ligands stimulate the kinase activity of RIPK1 to induce necroptosis (9, (11) (12) (13) (14) (15) (16) . RIPK1 also is recruited to the Toll-like receptor adapter TRIF via the Rip homotypic interaction motif (RHIM) to mediate NFκB activation (17) and, under conditions of caspase-8 inhibition, initiates necroptosis (14, 16) . Necrostatin-1 (Nec-1), an allosteric RIPK1 inhibitor, inhibits necroptosis induced by TNF or the TLR3 ligand poly I:C and abolishes the formation and activation of an RIPK1/3 complex (13) (14) (15) (16) 18) . Although the molecular details whereby RIPK1 initiates necroptosis are unclear, RIPK3 and the pseudo kinase MLKL appear to be required (2) .
Genetic studies in mice have revealed cross-regulation between the apoptotic and necroptotic pathways. For example, the FADD/caspase-8/FLICE-like inhibitory protein long form (FLIP L ) complex regulates RIPK1 and RIPK3 activity during development, because the embryonic lethality associated with a caspase-8 deficiency is completely rescued by the absence of RIPK3 (19, 20) . Similarly, RIPK1 deficiency rescues FADDassociated embryonic lethality (21) . Thus, in the absence of FADD or caspase-8, embryos succumb to RIPK1-and RIPK3-dependent necroptosis. However, Fadd −/− /Ripk1 −/− mice, die perinatally (21, 22) , as do Ripk1 −/− mice, revealing that RIPK1 has prosurvival roles beyond the regulation of the FADD/ caspase-8/FLIP L complex.
Significance
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in TNF signaling and interacts with the related RIPK3 to regulate cell death and inflammation. RIPK1 has kinase-independent prosurvival and kinase-dependent prodeath functions. To identify the lineages that depend on RIPK1 for survival, we generated conditional Ripk1 mice. Acute Ripk1 deletion results in rapid death of the animal caused by extensive cell death in the intestinal and hematopoietic lineages. A hematopoietic RIPK1 deficiency stimulates proinflammatory cytokine/chemokine production and cell death, resulting in bone marrow failure. Hematopoietic failure is partially rescued by a RIPK3 deficiency, indicating that RIPK1-deficient hematopoietic cells undergo RIPK3-mediated necroptosis. These findings show that in the hematopoietic lineage RIPK1 suppresses RIPK3 activity and suggest that RIPK-dependent necroptosis may contribute to human bone marrow failure syndromes.
We have demonstrated that complete RIPK1 deficiency results in increased TNF-induced cell death that can be rescued, in part, by the absence of the TNFR1 (22, 23) . However, Ripk1
animals still succumb (23) , indicating that other death ligands/ pathways contribute to the RIPK1-associated lethality. Consistent with this hypothesis, RIPK3 deficiency recently has been shown to rescue the perinatal lethality observed in Ripk1 (24, 25) . Similarly, combined caspase-8 and RIPK3 deficiency also rescues the RIPK1-associated lethality (24) (25) (26) . Collectively, these genetic studies in mice reveal that the perinatal death of Ripk1 −/− mice reflects TNF-induced apoptosis and RIPK3-mediated necroptosis. The nature of the ligand(s) or the trigger(s) of RIPK3-mediated necroptosis in vivo remain unclear. However, Ripk1
−/−
MEFs are prone to necroptosis induced by poly I:C or by treatment with type I or type II IFN (24, 25) , suggesting that these pathways contribute. Although these studies reveal a regulatory role for RIPK1, the multiorgan cell death and inflammation observed in the complete and compound RIPK1-knockout strains have made it difficult to discern the specific tissues that require RIPK1 for survival.
Results
To identify the cell types and lineages in the adult dependent on RIPK1 for survival, we mated conditional Ripk1 mice to the tamoxifen-inducible Rosa26CreER T2 transgenic mice (27) (Fig.  1A and Fig. S1A ). Administration of three daily injections of 1 mg of tamoxifen resulted in efficient RIPK1 depletion in RosaCreER T2 Ripk1 fl/fl mice and in the rapid induction of pathology in the intestinal and hematopoietic lineages ( Fig. 1 and Fig. S1 ). RosaCreER T2 Ripk1 fl/fl mice treated with tamoxifen developed diarrhea and weight loss and were killed 24 h after the third tamoxifen injection ( Fig. 1 B and C) . Histological analysis revealed loss of bone marrow cellularity and erosion of villus structures with pronounced loss of intestinal epithelial cells in the ileum and colon (Fig. 1B) Increased numbers of dying cells that stained positive for cleaved caspase-3 were detected in the thymus, spleen, and small and large intestines of RosaCreER T2 Ripk1 fl/fl mice, indicating that RIPK1 deficiency results in caspase-dependent apoptosis in these lineages ( Fig. S1 E and F). Cell death in thymus and spleen resulted in significant decreases in overall thymic and splenic cellularity (Fig. S1H) , features observed in mice with complete RIPK1 deficiency (22) . Cell death and/or inflammation was not evident in the other organs examined (Fig. S1G) , nor was there evidence of anemia, indicating that intestinal epithelial cell loss is likely the major contributing factor in the death of the tamoxifen-treated RosaCreER T2 Ripk1 fl/fl mice. Genomic PCR confirmed Ripk1 deletion in the intestines and the hematopoietic organs of tamoxifen-treated RosaCreER T2 Ripk1 fl/fl mice ( Fig. S1 B-D) . Tamoxifen-treated RosaCreER T2 mice did not develop intestinal or hemato-pathology.
RIPK1 deficiency resulted in decreases in the absolute number of lymphoid and myeloid cells (Fig. S1 I-K (Fig. 1D) . The LSK population was analyzed further by staining with CD34 and fetal liver kinase 2 (Flk2) antibodies to quantify the longand short-term hematopoietic stem cells (HSCs) and multipotent progenitors (MPPs), all of which were reduced significantly in RosaCreER T2 Ripk1 fl/fl mice (Fig. 1D ). To examine stem and progenitor cell function, we plated bone marrow from tamoxifen-treated RosaCreER T2 Ripk1 fl/fl or RosaCreER T2 control mice in an in vitro hematopoietic colony assay and observed >75% reduction in progenitor activity in the RIPK1-deficient cultures (Fig. 1E) . Collectively, these data show that acute ablation of RIPK1 in adult mice results in intestinal epithelial and hematopoietic cell death, revealing crucial prosurvival roles for RIPK1 in these lineages.
Hematopoietic cell death observed upon acute ablation of RIPK1 may be a secondary effect resulting from the inflammation induced by cell death in the intestine and potentially other lineages. Consistent with this possibility, serum proinflammatory chemokine and cytokine levels were increased significantly in tamoxifen-treated RosaCreER T2 Ripk1 fl/fl mice but not in controls (Fig. S2) Fig. 2 A and B) . Ripk1 deletion was detected in bone marrow, spleen, and thymus of these mice but not in nonhematopoietic tissues (Fig. S3A) . The Vav-iCre Ripk1 fl/fl mice developed marked pancytopenia and anemia with an average 38-fold decrease in bone marrow cellularity ( (Fig. S3 B-D) . Despite the hematopoietic cell loss, some of the Vav-iCre Ripk1 fl/fl mice exhibited mild to moderate inflammation characterized by focal areas of granulocyte infiltration in skin or liver (Fig. S3F ). These histologic findings indicate that hematopoietic RIPK1 deficiency can result in tissue inflammation.
These mouse genetic studies using hematopoietic or inducible Cre recombinase reveal crucial roles for RIPK1 in hematopoietic cell survival. To reveal the kinetics of hematopoietic cell death, we examined 2-wk-old Vav-iCre Ripk1 fl/fl mice for evidence of hematopoietic deficiency. We detected no significant decreases in peripheral blood counts or in the cellularity of the bone marrow or spleen, although modest decreases in the absolute numbers of T and B cells were evident in thymus, spleen, and bone marrow (Fig. S4 ). However, statistically significant decreases in absolute number of HSPCs and in colony-forming activity were observed ( Fig. 3 A and C) . HSPC number and colony formation in Vav-iCre Ripk1 fl/fl mice were reduced further at 5 wk ( Fig. 3 B and C) . The hematopoietic cell loss observed in these mice was associated with increases in serum chemokines including interferon gamma-induced protein-10 (IP-10), keratinocyte chemoattractant (KC), monocyte chemoattractant protein-1 (MCP-1), and monokine induced by γIFN (MIG), and proinflammatory cytokines (TNF-α, IFN-γ, IL-6, and G-CSF) (Fig. S5) . The anti-inflammatory cytokine IL-10 also was up-regulated, whereas the IFN-γ-regulated chemokine LPS-induced CXC chemokine (LIX) (the mouse ortholog of CXCL5) was significantly down-regulated in Vav-iCre Ripk1 fl/fl mice; these features also are observed in human patients with bone marrow failure (29) (30) (31) . These data suggest that RIPK1 deficiency sensitizes HSPCs to cytokine-mediated cell death. To test this hypothesis, we isolated bone marrow from 14-d-old Vav-iCre Ripk1 fl/fl mice and added TNF, TNF-related apoptosis-inducing ligand (TRAIL), or type I or type II IFN to the hematopoietic colony assays. Colony number and size were reduced significantly when the RIPK1-deficient progenitors were cultured with TNF or with type I or type II IFN but not when cultured with TRAIL; these findings indicate that, in addition to TNF, RIPK1-deficient hematopoietic progenitors also are sensitive to cell death induced by type I or type II IFN (Fig. 3D) .
RIPK1 deficiency had clear effects on all the hematopoietic lineages examined (Figs. 2 and 3 and Fig. S3 ). Mice deficient in RIPK1 also were significantly smaller than littermate controls ( Fig. 2A) , and most of these mice exhibited focal areas of inflammation (Fig. S3 ). To determine whether RIPK1 has a hematopoietic cell-intrinsic survival function, we transplanted embryonic day 14.5 fetal liver cells from Vav-iCre Ripk1 fl/fl mice and littermate controls into lethally irradiated syngeneic recipients and monitored the relative contributions of donor and host cells to hematopoiesis (Fig. 4A ). Mice transplanted with RIPK1-deficient fetal liver cells exhibited significant reductions in the HSPC population as early as 2 wk posttransplantation (Fig.  4B ). Eight weeks after transplantation, the RIPK1-deficient HSPC populations were nearly undetectable in the transplanted mice (Fig. 4C) , confirming that RIPK1 has a cell-intrinsic survival function in HSPC.
Although cleaved caspase-3 + hematopoietic cells were detected in the thymus and spleen, dying cells that were negative for cleaved caspase-3 were observed in the RIPK1-deficient bone marrow and spleen, suggesting that some hematopoietic cells die from necrosis rather than apoptosis. We hypothesized that the HSPC death in Vav-iCre Ripk1 fl/fl mice could reflect RIPK3-dependent necroptosis. To address the potential role of RIPK3, we generated and analyzed Vav-iCre Ripk1 fl/fl Ripk3 −/− mice. In contrast to Ripk1 −/− Ripk3 −/− double-knockout mice, which die during the postnatal period (24-26), Vav-iCre Ripk1 fl/fl
Ripk3
−/− mice develop normally and reach adulthood without showing any macroscopic or histologic abnormalities (Fig. 5 A, B , and E). Remarkably, RIPK3 deficiency rescued the pancytopenia, anemia, and bone marrow hypocellularity associated with fl/fl (n = 3) mice. Total colony number was normalized to vehicle-treated bone marrow. Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001. hematopoietic RIPK1 deficiency (Fig. 5 C-E) . These genetic data reveal that, in the absence of RIPK1, hematopoietic cells undergo RIPK3-mediated necroptosis. Thus, in contrast to published studies showing that RIPK1 is essential for TNF-and Fas-mediated (9, 12, 13, 24, 25, 32) 
Rather, our data suggest that RIPK1 functions in the hematopoietic lineage to prevent RIPK3-initiated necroptosis. Consistent with the notion that necroptosis constitutes an inflammatory form of cell death, we found serum cytokines and chemokines (TNF-α, IFN-γ, IL-6, IP-10, KC, MCP-1, MIG, IL-10, and G-CSF) up-regulated in Vav-iCre Ripk1 fl/fl mice (Fig. S5) ; however, cytokine/chemokine levels were significantly reduced in Vav-iCre Ripk1 fl/fl
−/− mice, in which necroptotic death was prevented (Fig. 5 F  and G) . Furthermore, Vav-iCre Ripk1 fl/fl Ripk3 −/− HSPCs no longer appeared as sensitive to γ-or α-IFN-induced cell death but retained sensitivity to TNF-induced apoptosis (Fig. 5H) . These in vitro colony data suggest that RIPK1-deficient HSPCs undergo TNF-induced apoptosis and RIPK3-mediated necroptosis potentially triggered by TNF and/or type I or type II interferons.
Analysis of the LSK population in Vav-iCre Ripk1 fl/fl Ripk3 −/− mice revealed that the absence of RIPK3 did not completely rescue the absolute numbers of HSPC or in vitro colony formation ( Fig. 5I and Fig. S6F bone marrow cells. Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t test in B, C, H, and I; Mann-Whitney test in F and G).
Vav-iCre Ripk1 fl/fl Ripk3 −/− bone marrow cells died (Fig. 5J) (37), suggesting that the kinase activity of RIPK1 is not required to regulate RIPK3 activity. Moreover, genetic rescue appears specific to the hematopoietic and skin lineages (26, 38) , because RIPK3 deficiency has marginal effects on the overall survival of RIPK1-deficient mice (24) (25) (26) .
In both the inducible and hematopoietic lineage knockout models, the HSPC population appears particularly dependent on RIPK1 for survival. Twenty-four hours after the final tamoxifen injection, we observe an 8-to 10-fold decrease in HSPCs with more modest reductions in lineage-restricted cells (Fig. 1D and Fig. S1 I-K) . Consistently, the absolute numbers of HSPCs are reduced in 2-wk-old Vav-iCre Ripk1 fl/fl mice and become nearly undetectable by age 5 wk.
Our data suggest that hematopoietic RIPK1 deficiency is sufficient to stimulate necroptosis and cytokine/chemokine production and/or release; however, these mice develop only mild tissue inflammation before succumbing to hematopoietic failure. Therefore, it remains unclear from these studies whether hematopoietic RIPK1 deficiency is sufficient to trigger systemic inflammation. What triggers hematopoietic necroptosis in Vav-iCre Ripk1 fl/fl mice also is unknown. Hematopoietic cell death may reflect unregulated RIPK3 activity and be independent of receptor signaling (as suggested in ref. 39 ). Alternatively, necroptosis may be triggered by infection, stress, and/or injury or by the transition from the fetal liver to the bone marrow microenvironment. It also is possible that hematopoietic RIPK1 deficiency stimulates the degradation of prosurvival proteins cIAP1/2 and TRAF2, thereby making cell death more likely. In addition to mediating survival, the IAPs have been shown to regulate TNF production; thus RIPK1 deficiency may promote cell death and induce inflammation via effects on cIAP1/2 protein stability (40) (41) (42) . Increased chemokine and cytokine production also are features associated with the rapid HSPC death observed in the RosaCreER
T2
Ripk1
fl/fl model (Fig. S2 ). Hence we propose that hematopoietic RIPK1 deficiency results in RIPK3-mediated necroptosis, DAMP release, and inflammation. Consistent with this model, RIPK3 deficiency significantly reduces serum cytokine and chemokine levels and inhibits the hematopoietic cell death observed in Vav-iCre Ripk1 fl/fl mice (Fig. 5 D-G and Fig. S6 ).
In addition to TNF, RIPK1-deficient MEF are sensitive to necroptosis induced by type I or type II IFN treatment (24, 25, 43) . We find that TNF-α, IFN-α, and IFN-γ, but not TRAIL, reduce the hematopoietic colonies derived from RIPK1-deficient progenitors (Fig. 3D) . TNF-α and IFN-γ levels are up-regulated in patients with bone marrow failure (44) (45) (46) and in both mouse models of RIPK1 deficiency, suggesting that TNF-α and IFN-γ may trigger apoptosis and/or RIPK3-dependent necroptosis in vivo. Our in vitro studies reveal that Vav-iCre Ripk1 fl/fl Ripk3 −/− progenitors remain sensitive to TNF-induced apoptosis but appear to be protected from IFN-mediated necroptosis (Fig. 5H) . In contrast to the lineage-restricted cells, which are rescued in Vav-iCre Ripk1 fl/fl Ripk3 −/− mice, the HSPCs remain significantly reduced, suggesting that the RIPK1-and RIPK3-deficient progenitors undergo apoptosis. In fact, our transplantation studies demonstrate that these progenitors are unable to reconstitute hematopoiesis fully in irradiated mice (Fig. 5J) . Therefore, RIPK3 deficiency reduces inflammation but rescues only short-term hematopoiesis in mice reconstituted with RIPK1-deficient TNF-α and IFN-γ overproduction are features associated with human bone marrow failure syndromes such as Fanconi anemia (FA) and aplastic anemia. FA patients exhibit a profound defect in HSPC that is present before the onset of clinical bone marrow failure (49) . In addition to interstrand cross-linking agents, FA patient cells also are hypersensitive to IFN-γ-and TNFinduced cell death (50) , raising the intriguing possibility that the progressive HSPC elimination observed in these patients reflects, in part, TNF-and/or IFN-γ-induced RIPK-dependent necroptosis. It has been speculated that FA patients may benefit from treatments aimed at inhibiting proinflammatory cytokine production. Thus, our findings may have translational implications for these patients as highly selective RIPK1 and RIPK3 inhibitors are being developed.
Materials and Methods
Mice. Ripk1 conditional mice (Ripk1 fl/fl ) (38) were crossed with Ripk3 −/− mice (a generous gift from Vishva Dixit, Genentech, San Francisco), Vav-iCre (28) or ROSA26-CreER T2 (27) mice (obtained from Jackson Laboratory). When mice became moribund, they were weighed and killed humanely. Complete blood counts and hematocrits were performed on a Hemavet 950FS analyzer (Drew Scientific). For bone marrow transplantation studies, recipient C57BL/6 CD45.1 mice received 11 Gy of total body irradiation in a split dose (550 rads) with a 4-h rest between doses using a Cesium-137 irradiator. Irradiated recipients were reconstituted by i.v. injection of 2 × 10 6 E14.5 fetal liver cells or bone marrow cells. Recipients were maintained on medicated water and monitored daily for signs of failed engraftment. For Vav-iCre Ripk1 fl/fl transplants mice were killed at 2 and 8 wk after reconstitution. All animal procedures used in this study were approved by The University of Massachusetts Medical School Institutional Animal Care and Use Committee.
Histology. Tissues were fixed in 10% formalin (Fisher Scientific), and bone marrow was decalcified in Cal-Rite (Richard Allen Scientific) for 48 h. Samples were stained with H&E or with a cleaved caspase-3 antibody (Cell Signaling) at a 1:200 dilution. Images were taken at 10-20× magnification on an Olympus BX41 microscope using an Evolution MP 5.0 Mega-Pixel Camera (MediaCybernetics) and QCapture Pro software (QImaging).
Colony-Forming Assay. Bone marrow cells were seeded in MethoCult medium M3434 (STEMCELL Technologies), and total colony number was determined following the manufacturer's protocol. Ligands were added at the time of plating at the following concentrations: mTRAIL, 200 ng/mL (Pepro Tech); mTNF-α, 10 ng/mL (RandD); mIFN-α 100 units/mL (PBL Interferon Source); mIFN-γ, 10 ng/mL (Pepro Tech).
Flow Cytometry. Single-cell suspensions were stained with cell-surface antibodies for myeloid (Gr-1 and CD11B) and lymphoid (CD3, CD4, CD8, B220) markers. For LSK analysis, bone marrow cells were stained with a biotin lineage mixture, Sca-1, c-Kit, CD34, and Flk2. To distinguish between donor and host hematopoietic cells in the transplant studies, an anti-CD45.2 antibody was added to the LSK staining mixture. All samples were run on a BD LSRII flow cytometer (BD Bioscience) and analyzed using FlowJo software (Tree Star). A complete list of antibodies including clone numbers is given in Table S1 .
Serum Cytokines. Serum cytokines were measured using a 12-plex protein/ peptide multiplex analysis (Luminex Technology) conducted by the National Mouse Metabolic Phenotyping Center at the University of Massachusetts Medical School. Chemokines and cytokines that were below the level of detection were assigned the value of zero.
Statistical Measures. Statistical analyses were performed using GraphPad Prism software, version 6.0. Kaplan-Meier survival curves were analyzed using a log rank test with a 95% confidence interval. A two-sided P < 0.05 was considered statistically significant for Student's t tests and nonparametric Mann-Whitney tests. fl/fl mice. Error bars represent SEM. *P < 0.05, **P < 0.01 ***P < 0.0001 (Student's t tests). 
